DotBio specializes in next-generation antibody therapies, leveraging its proprietary DotBody technology platform, which is founded on modular design principles. This innovative approach allows for the prefabrication of antibody modules with specific functions, enabling the rapid assembly of multi-functional antibodies, including bi- and tri-specific antibodies, antibody-drug conjugates (ADCs), and intracellular antibodies. The platform's high throughput capabilities facilitate the generation of numerous prototypes in parallel, significantly reducing development time and streamlining the identification of optimal therapeutic candidates. DotBio's technology is designed to target a variety of disease drivers, particularly in cancer, by utilizing a constantly expanding bank of DotBody modules that focus on specific targets such as HER2, EGFR, and immune checkpoints.

In addition to the DotBody technology, DotBio employs several advanced methodologies to enhance the stability and efficacy of its therapeutic candidates. The Hot-Colony Filtration (Hot-CoFi) technology is utilized to improve the stability and solubility of DotBodies, ensuring a better safety profile and developability of the molecules. Furthermore, DotBio incorporates phage display technology to isolate and generate its DotBody modules, allowing for the creation of therapeutic molecules with high affinity and specificity. This combination of modular design, rapid prototyping, and advanced stabilization techniques positions DotBio at the forefront of antibody therapy development, with a focus on innovative solutions for cancer treatment.

Singapore

DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Pär Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody engineering at Singapore’s Nanyang Technological University. 

DotBio

Company Details